Dermata Therapeutics, Inc.
NASDAQ Capital MarketTotal Valuation
Dermata Therapeutics, Inc. carries a market capitalization of 7,906.00, placing it among publicly traded companies globally. Its enterprise value stands at -6.95M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 7,906.00 |
| Enterprise Value | -6.95M |
Share Statistics
Dermata Therapeutics, Inc. currently has 4.02M shares outstanding.
| Shares Outstanding | 4.02M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Dermata Therapeutics, Inc. maintains a current ratio of 7.09, meaning it holds 7.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 7.09 |
| Quick Ratio | 6.60 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -81.31 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Dermata Therapeutics, Inc.'s stock has declined approximately -26.11465% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.02.
| Beta (5Y) | N/A |
| 52-Week Price Change | -26.11465% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.02 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -7.36M, while operating income came in at -7.36M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -7.36M |
| Pretax Income | -7.10M |
| Net Income | -7.10M |
| EBITDA | -7.36M |
| EBIT | -7.36M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Total book value stands at -75.08M, with working capital of 6.41M providing operational flexibility.
| Cash & Cash Equivalents | 6.95M |
| Total Debt | N/A |
| Net Debt | -6.95M |
| Equity (Book Value) | -75.08M |
| Book Value Per Share | N/A |
| Working Capital | 6.41M |
Cash Flow
Dermata Therapeutics, Inc. produced -8.30M in operating cash flow over the past twelve months.
| Operating Cash Flow | -8.30M |
| Capital Expenditures | N/A |
| Free Cash Flow | -8.30M |
| FCF Per Share | N/A |
Scores
Dermata Therapeutics, Inc. posts an Altman Z-Score of -16.30, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -16.30 |